Urgent clinical commissioning policy statement: Vestronidase alfa for Mucopolysaccharidosis Type VII (MPS, Sly syndrome) (infantile)

Document first published:
Page updated:
Topic:
,
Publication type:

Vestronidase alfa is recommended to be available as a routine commissioning as a treatment option for infants with MPS VII within the criteria set out in this document.

Document

Urgent clinical commissioning policy statement: Vestronidase alfa for Mucopolysaccharidosis Type VII (MPS, Sly syndrome) (infantile)

Urgent clinical commissioning policy statement: Vestronidase alfa for Mucopolysaccharidosis Type VII (MPS, Sly syndrome) (infantile)

  • PDF
  • 477 KB
  • 17 pages